Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HRA Pharma Rare Diseases
Châtillon, Francehra-pharma-rare-diseases.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
HRA Pharma Rare Diseases is a specialized pharmaceutical company dedicated to improving the lives of patients with rare diseases, primarily in the field of endocrinology. The company focuses on the development and commercialization of orphan drugs for conditions with high unmet medical needs, such as Cushing's syndrome and Adrenocortical Carcinoma. Its commercial portfolio includes established therapies like Metopirone, Lysodren, and Ketoconazole HRA. Originally a business unit of HRA Pharma, the entity was acquired by Perrigo in 2022 and continues to operate as a leader in niche endocrine oncology and rare metabolic disorders.
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on HRA Pharma Rare Diseases.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRA Pharma Rare Diseases.